<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033029</url>
  </required_header>
  <id_info>
    <org_study_id>HCC-PIP-2018-01</org_study_id>
    <nct_id>NCT04033029</nct_id>
  </id_info>
  <brief_title>Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)</brief_title>
  <official_title>Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Study: Open label, non-randomized, observational, descriptive and prospective
           pharmacokinetic.

        -  Patients: sepsis patients undergoing continuous renal replacement therapy (CRRT) and
           admitted at the Intensive care unit of Bellvitge University Hospitals. No power
           calculations needed.

        -  Antibiotic treatment: piperacillin, ceftazidime, cefepime, ceftolozane and daptomycin as
           their standard of care and doses will be at the discretion of the treating physician.

        -  CRRT treatment: continuous venovenous hemodiafiltration (CVVHDF) will be performed by
           using the PrismafleX eXeed™ system with a high adsorbent membrane (oXiris®).

        -  Antibiotic concentrations: blood pre and post filter, urine and ultrafiltrate samples
           will be collected at steady state conditions. Samplig time will depend on dosage
           regimens of each antibiotic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open label, non-randomized, observational, descriptive and prospective
      pharmacokinetic study.

      Setting: this study will be conducted at the Intensive Care Unit at the Bellvitge University
      Hospital.

      Study aims: the primary objective is to determine the PK/PD target attainment of
      piperacillin, ceftazidime, cefepime, ceftolozane and daptomycin in septic critically ill
      patients treated with CVVHDF using oXiris® membrane. Secondary aims are: i) to characterize
      the PK of piperacillin, ceftazidime, cefepime, ceftolozane and daptomycin in critically ill
      patients under CVVHDF therapy using oXiris® membrane by developing a population PK model; ii)
      to identify the clinical and demographic sources of PK variability observed in these patient
      and iii) to develop individualized dosing recommendations based on the PK/PD index associated
      with therapy success.

      Recruitment process: patients who meet the inclusion criteria will be enrolled for at least
      72 hours (maximum 96 hours).

      Sample size: no power calculations are required for this study as it aims to investigate the
      PK of these antibiotics and does not intend to measure the effect of an intervention between
      two groups.

      Antibiotic treatment: patients will receive piperacillin, ceftazidime, cefepime,
      ceftolozane/tazobactam or daptomycin as their standard of care. Doses will be at the
      discretion of the treating physician. At the same time, patients will be treated under
      continuous renal replacement techniques (CRRT) with continuous venovenous hemodiafiltration
      mode (CVVHDF) using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane
      (oXiris®). Filtration parameters will be determined following the local protocol (dose of
      25-30 ml/kg/h) CRRT initiation will be determined by the treating physician on charge,
      according with the current recommendations of clinical practice and prescriptions of CRRT and
      local management protocols. The decision to stop the treatment will be determined by:

        -  Adequate renal recovery status: adequate capacity to effectively maintain fluid and
           electrolyte homeostasis and urinary output (&gt;450 ml in 24 h) without the use of
           diuretics.

        -  Hemodynamic stability without renal function recovery. Therapy will be continued as
           intermittent hemodialysis.

      Antibiotic concentrations: blood, either pre and post filtration through oXiris® membrane,
      urine and ultrafiltrate samples will be obtained. Samples will be collected at 1) steady
      state conditions and 2) after minimum 24h from the concomitant administration of CRRT and
      antibiotic for piperacillin, ceftazidime, cefepime, ceftolozane and 48h for daptomycin.
      Sampling times will depend on the dosage regimen of each antibiotic therapy. Drug
      concentrations will be determined using a previously developed and validated measurement
      procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of individuals attaining a defined pharmacokinetic-pharmacodynamic target for antimicrobial therapy</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>Time above minimum inhibitory concentration (%fT &gt; k× MIC) for betalactams, and total-drug AUC24/MIC ≥ 666 for daptomycin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibiotic concentration-time data.</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>Antibiotic concentration-time data will be collected and analysed to characterize the PK profile of piperacillin, ceftazidime, cefepime, ceftolozane and daptomycin in critically ill patients under CRRT therapy using oXiris® membrane and a population PK model will be developed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood flow (mL/min). CRRT covariate that can affect drug exposure and PK parameters.</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>Effect of CRRT settings, physiopathological and demographic data on drug exposure and PK parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysate flow rate (L/h).</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>CRRT covariate that can affect drug exposure and PK parameters. For each antibiotic, a population pharmacokinetic model will be developed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrafiltrate flow rate (L/h).</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>CRRT covariate that can affect drug exposure and PK parameters. For each antibiotic, a population pharmacokinetic model will be developed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Replacement fluid (mL/h).</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>CRRT covariate that can affect drug exposure and PK parameters. For each antibiotic, a population pharmacokinetic model will be developed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extraction rate (L/h).</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>CRRT covariate that can affect drug exposure and PK parameters. For each antibiotic, a population pharmacokinetic model will be developed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine output (mL/day).</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>Physiopathological variables that can affect drug exposure and PK parameters. For each antibiotic, a population pharmacokinetic model will be developed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin (g/L).</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>Physiopathological variables that can affect drug exposure and PK parameters. For each antibiotic, a population pharmacokinetic model will be developed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (Kg).</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>Physiopathological variables that can affect drug exposure and PK parameters. For each antibiotic, a population pharmacokinetic model will be developed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission diagnosis: surgical, medical, trauma.</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>Physiopathological variables that can affect drug exposure and PK parameters. For each antibiotic, a population pharmacokinetic model will be developed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage (mg, frequency of administration and mode of administration) needed to achieve the PK/PD target.</measure>
    <time_frame>01/08/2019 - 31/12/2021</time_frame>
    <description>Monte-Carlo Simulations using the population PK parameters of the final models in order to generate concentration-time profiles of n hypothetical subjects per dosing regimen will be performed. With this data, we will calculate the probability of target attainment of the PK/PD indices associated to antibiotic therapy success, which will translate in the development of individualized dosing recommendations for our patient population.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hemodiafiltration</condition>
  <condition>Sepsis</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Patients under CVVHDF with high adsorption membrane</arm_group_label>
    <description>Continuous venovenous hemodiafiltration mode (CVVHDF) using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)</intervention_name>
    <description>CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).</description>
    <arm_group_label>Patients under CVVHDF with high adsorption membrane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Antibiotic concentration-time data will be collected and analyzed.</description>
    <arm_group_label>Patients under CVVHDF with high adsorption membrane</arm_group_label>
    <other_name>Piperacillin/tazobactam</other_name>
    <other_name>Ceftazidime</other_name>
    <other_name>Cefepime</other_name>
    <other_name>Daptomycin</other_name>
    <other_name>Ceftolozane/tazobactam</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, ultrafiltrate and urine samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients under continuous venovenous hemodiafiltration (CVVHDF) by using the
        PrismafleX eXeed™ system with a high adsorbent membrane (oXiris®) and requiring antibiotic
        treatment with: piperacillin, ceftazidime, cefepime, ceftolozane/tazobactam or daptomycin.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in the setting of sepsis and requirements of CRRT with high adsorption
             membranes for at least 48 h

          -  Age &gt;18 years

          -  Treatment with piperacillin, ceftazidime, cefepime, ceftolozane and daptomycin
             prescribed at the discretion of the treating intensive care physician.

          -  Written informed consent will be required before the inclusion of a patient whenever
             possible and will be requested from the nearest relatives in the other cases.

        Exclusion Criteria: none.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Colom Codina, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitat Autònoma de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helena Colom Codina, Phd</last_name>
    <phone>932607504</phone>
    <phone_ext>7504</phone_ext>
    <email>helena.colom@ub.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariadna Padullés Zamora, Phd</last_name>
    <phone>932607504</phone>
    <phone_ext>7504</phone_ext>
    <email>apadulles@bellvitgehospital.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helena Colom Codina</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Helena Colom Codina, Phd</last_name>
      <phone>932607504</phone>
      <phone_ext>7504</phone_ext>
      <email>helena.colom@ub.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ariadna Padullés Zamora, Phd</last_name>
      <phone>932607504</phone>
      <phone_ext>7504</phone_ext>
      <email>apadulles@bellvitgehospital.cat</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009 Dec 2;302(21):2323-9. doi: 10.1001/jama.2009.1754.</citation>
    <PMID>19952319</PMID>
  </reference>
  <reference>
    <citation>Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000;26 Suppl 1:S64-74. Review.</citation>
    <PMID>10786961</PMID>
  </reference>
  <reference>
    <citation>Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999 Feb;115(2):462-74.</citation>
    <PMID>10027448</PMID>
  </reference>
  <reference>
    <citation>Zaragoza R, Artero A, Camarena JJ, Sancho S, González R, Nogueira JM. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect. 2003 May;9(5):412-8.</citation>
    <PMID>12848754</PMID>
  </reference>
  <reference>
    <citation>Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care. 2002 Apr;30(2):134-44. Review.</citation>
    <PMID>12002919</PMID>
  </reference>
  <reference>
    <citation>Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000 Jul;118(1):146-55.</citation>
    <PMID>10893372</PMID>
  </reference>
  <reference>
    <citation>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2. Review.</citation>
    <PMID>9455502</PMID>
  </reference>
  <reference>
    <citation>Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Crit Care Med. 2009 Mar;37(3):926-33. doi: 10.1097/CCM.0b013e3181968e44.</citation>
    <PMID>19237898</PMID>
  </reference>
  <reference>
    <citation>Heinemeyer G, Link J, Weber W, Meschede V, Roots I. Clearance of ceftriaxone in critical care patients with acute renal failure. Intensive Care Med. 1990;16(7):448-53.</citation>
    <PMID>2269714</PMID>
  </reference>
  <reference>
    <citation>Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005 Oct 15;41(8):1159-66. Epub 2005 Sep 12. Review.</citation>
    <PMID>16163635</PMID>
  </reference>
  <reference>
    <citation>Carcelero San Martín E, Soy Muner D. [Dosage of antipseudomonal antibiotics in patients with acute kidney injury subjected to continuous renal replacement therapies]. Med Intensiva. 2013 Apr;37(3):185-200. doi: 10.1016/j.medin.2012.02.012. Epub 2012 Apr 3. Review. Spanish.</citation>
    <PMID>22475763</PMID>
  </reference>
  <reference>
    <citation>Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother. 2000 Jun;44(6):1639-44.</citation>
    <PMID>10817721</PMID>
  </reference>
  <reference>
    <citation>Bauer SR, Salem C, Connor MJ Jr, Groszek J, Taylor ME, Wei P, Tolwani AJ, Fissell WH. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT. Clin J Am Soc Nephrol. 2012 Mar;7(3):452-7. doi: 10.2215/CJN.10741011. Epub 2012 Jan 26.</citation>
    <PMID>22282479</PMID>
  </reference>
  <reference>
    <citation>Valtonen M, Tiula E, Backman JT, Neuvonen PJ. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2000 May;45(5):701-4.</citation>
    <PMID>10797097</PMID>
  </reference>
  <reference>
    <citation>Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R; RENAL Replacement Therapy Study Investigators. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012 May;40(5):1523-8. doi: 10.1097/CCM.0b013e318241e553.</citation>
    <PMID>22511133</PMID>
  </reference>
  <results_reference>
    <citation>Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011;15(3):R137. doi: 10.1186/cc10257. Epub 2011 Jun 6.</citation>
    <PMID>21649882</PMID>
  </results_reference>
  <results_reference>
    <citation>Rigo-Bonnin R, Ribera A, Arbiol-Roca A, Cobo-Sacristán S, Padullés A, Murillo Ò, Shaw E, Granada R, Pérez-Fernández XL, Tubau F, Alía P. Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of β-lactam antibiotic concentration in human plasma. Clin Chim Acta. 2017 May;468:215-224. doi: 10.1016/j.cca.2017.03.009. Epub 2017 Mar 10.</citation>
    <PMID>28288784</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Helena Colom Codina</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute kidney Injury</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Antibiotic plasma level</keyword>
  <keyword>CRRT</keyword>
  <keyword>oXiris®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

